Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On ...

Learn about side effects, cost, uses, and more of Filspari (sparsentan), which is a prescription drug that helps manage IgA nephropathy in adults.

The potential approval of FILSPARI for FSGS by September 2025 could mark a critical milestone, expanding its addressable market and reinforcing its leadership in rare kidney diseases.

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's ...

FILSPARI (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney by blocking two critical pathways of IgAN disease progression ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. The FDA has converted Filspari’s conditional nod in the kidney disease IgA nephropathy (IgAN) into a ...

SAN DIEGO, June 03, 2025--Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (Nasdaq: TVTX ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics ...